Ductal carcinoma in situ of the breast has rapidly increased in incidence over the past several decades secondary to an increased use of screening mammography. Local treatment options for women diagnosed with ductal carcinoma in situ include mastectomy or breastconserving therapy. Although several randomized trials have confirmed a >50% reduction in the risk of local recurrence with the administration of radiation therapy (RT) compared with breast-conserving surgery alone, controversy persists regarding whether or not RT is needed in selected "low-risk" patients. Over the past two decades, two prospective single-arm studies and one randomized trial have been performed and confirm that the omission of RT after surgery is associated with higher rates of local recurrence even after selecting patients with optimal clinical and pathologic features. Importantly, these trials have failed to consistently and reproducibly identify a low-risk cohort of patients (based on clinical and pathologic features) that does not benefit from RT. As a result, adjuvant RT is still advocated in the majority of patients, even in low-risk cases. Future research is moving beyond traditional clinical and pathologic risk factors and instead focusing on approaches such as multigene assays and biomarkers with the hopes of identifying truly low-risk patients who may not require RT. However, recent studies confirm that even low-risk patients identified from multigene assays have higher rates of local recurrence with local excision alone than would be expected with the addition of RT.
D uctal carcinoma in situ (DCIS) of the breast represents up to one quarter of all new breast neoplasms diagnosed in the United States, with an increasing incidence noted over the past three decades secondary to increases in mammographic screening. 1 The local management of DCIS has traditionally paralleled that of early-stage invasive cancer as no randomized trials have directly compared mastectomy and breast-conserving therapy (BCT). Currently, BCT, consisting of breastconserving surgery (BCS) with adjuvant radiation therapy (RT), is considered the standard of care with regard to local management for eligible patients; although use of BCT in DCIS has increased over the past few decades, recent data have demonstrated a trend for increased rates of mastectomy utilization despite equivalent outcomes and improved quality of life with breast conservation. 2-6 Further, among those patients who elect for BCS, up to 50% do not receive adjuvant RT. 5, 7, 8 Therefore, the purpose of this systematic review is to examine the evidence supporting adjuvant RT, attempts to identify lowrisk subsets of patients, and to examine various local treatment options in the contemporary management of DCIS.
MATERIALS AND METHODS
This systematic review was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 9 No official review protocol was created for this systematic review. Eligibility criteria for this review included published studies in English between 1992 and 2012 evaluating patients with DCIS treated with or without radiotherapy; required information included the number of patients, length of follow-up, RT (yes/no, detailed analysis not required for studies to be reviewed), outcomes (local control outcomes at a minimum), and institution/source of data (to ensure no duplication). A 20-year interval of publication was chosen to focus on more recent literature, which included modern surgical and radiation techniques. Sources of information for the review included Medline/PubMed, those found in references from articles identified, and articles known to the authors. The PubMed search was conducted by a single author (C.S.) to identify any and all articles addressing DCIS and RT with the following MeSH headings: DCIS, ductal carcinoma in situ, radiation therapy, excision, mastectomy, outcomes, low risk. When multiple updates from a single institution were available, the most recent data were utilized unless results presented were unique to each study. All searches were completed by January 2, 2014.
Four separate searches were performed: (1) BCT (BCS + RT), (2) BCS alone, (3) studies of low-risk patients (including BCT and BCS studies), and (4) mastectomy for DCIS. When evaluating long-term ( > 10 y) outcomes following BCT in DCIS, a total of 149 articles were identified including 10 known to the authors; after review by a single author (C.S.), 103 were excluded. The remaining 46 studies were evaluated and 16 were found to have documented methodology and sufficient data to be incorporated into the review including 6 randomized trials, 1 meta-analysis, and 9 retrospective studies ( Fig. 1 ). With regard to data on the omission of RT (BCS), due to the quality of evidence available, focus was placed on randomized trials, prospective single-arm studies, meta-analyses, and large retrospective series. A total of 1394 articles were identified; after review, 7 randomized trials, 2 prospective single-arm trials, 2 metaanalyses, and 3 large retrospective series were felt to be of sufficient quality to include in the review. As quality metaanalyses were already available and published in peer-reviewed journals, data were not pooled. The search for publications evaluating low-risk DCIS patients (treated with BCT or BCS) identified 153 articles with 104 excluded. The remaining 49 articles were reviewed and 21 were found to be appropriate, including 2 randomized trials, 2 single-arm prospective trials, 2 meta-analyses, 3 evidence-based guidelines, 1 nomogram, and 11 retrospective studies. The search evaluating mastectomy for DCIS identified a total of 557 articles with 450 excluded. The remaining 107 studies were evaluated and 17 were found to have documented methodology and sufficient data to be incorporated into the review, including 2 meta-analyses and 15 single institution/retrospective studies.
RESULTS

BCT for DCIS With Radiotherapy: Long-term Results
As noted above, no randomized trials directly comparing mastectomy versus BCT (BCS + RT) have been performed in patients with DCIS. Therefore, the efficacy of BCT is often extrapolated from randomized trials in patients with earlystage invasive cancers, which have confirmed that BCT is not associated with inferior outcomes and provides equivalent survival to mastectomy. [10] [11] [12] There are numerous retrospective studies that have directly evaluated the long-term efficacy of BCS with adjuvant RT in patients with DCIS. Solin and colleagues followed 1003 patients who were treated at 10 institutions with all patients receiving WBI. With a median followup of 8.5 years, 10% of patients developed local failures (15 y rate: 19%) and the 15-year cause-specific survival was 98%. 13 Similar results have been noted from several institutions; data from William Beaumont Hospital, with a median follow-up of 19.3 years, found the 10-, 15-, and 20-year local recurrence rates following BCS with RT to be 12.2%, 13.7%, and 17.5%, respectively, which was confirmed by several studies with long-term follow-up that are presented in Table 1 . [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Additional data on the long-term efficacy of BCT in patients with DCIS can be found in the control arms of the 4 randomized trials evaluating the role of RT in patients treated with BCS. [16] [17] [18] [19] More recent efficacy data on BCT for DCIS are available from the NSABP B-24 study, which evaluated the role of tamoxifen in patients with DCIS undergoing BCT and the RTOG 9804 phase III trial, which evaluated the omission of RT in patients with low-risk DCIS. 16, 20 In the 4 randomized trials that examined the efficacy of adjuvant RT following BCS, patients treated with RT had a local recurrence rate of 10% to 15% at 10 years with 15-year outcomes from NSABP B-17 and EORTC 10853 finding local recurrence rates of 18% to 20%. [16] [17] [18] [19] 30 The Early Breast Cancer Trialists Group metaanalysis of these 4 trials found the 10-year rate of ipsilateral breast tumor recurrence (IBTR) to be 13% for those patients undergoing BCT with adjuvant RT. 31 In the NSABP B-24 trial, the 15-year rates of IBTR were 8.5% to 10% for the 2 arms that underwent BCT. 16 More recently, the RTOG 9804 trial randomized 636 patients to observation alone or RT with or without tamoxifen following BCS. As this represents a lower risk cohort of patients than the previously discussed studies, the 5-year rate of IBTR was 0.4% with adjuvant RT. 20 It should be noted that recent local control outcomes for patients undergoing BCT seem to be improved compared with older trials. For example, a retrospective review of 246 patients with DCIS undergoing BCT between 2001 and 2007 at Harvard University demonstrated a 0% rate of IBTR with 58 months of follow-up. 23 Similar findings were noted by Nelson et al 24 when evaluating a modern cohort of 609 patients with 10-year local recurrence rates of only 4.2% to 7.2%. In summary, patients undergoing BCS with the addition of adjuvant RT have 10-year rates of IBTR of 10% to 15% based on older series (retrospective and prospective studies) and 0% to 7% based on more recent data. With 15 years of follow-up, older series have found the rate of IBTR to be in the range of 15% to 20% (Table 1) .
Breast conserving therapy outcomes
Omission of Radiotherapy
BCT for DCIS Without Adjuvant Radiotherapy
As previously discussed, 4 randomized trials have been conducted evaluating the role of RT following BCS, enrolling a total of 4596 patients with DCIS. Women enrolled on these trials are different than most patients with DCIS today in that none received endocrine therapy (except for the UKCCR trial), negative margins were not required in all series, and a larger percentage of cases were clinically detected compared with current series. NSABP B-17 randomized 818 patients following BCS to observation alone or whole breast irradiation (WBI) (50 Gy); at 15 years, WBI significantly reduced the rate of IBTR (17.7% vs. 35 .1%) with no difference in survival reported. 16, 30 Similar findings were noted from the EORTC 10853 trial and Swedish DCIS trials, which found that WBI reduced the rate of IBTR with no survival benefit. 17, 18 It should be noted that a small randomized trial from Hungary, which accrued patients between 2000 and 2007, found no difference in recurrence rates although only 29 patients were accrued. 32 The UKCCR trial was different from the first 3 trials, in that it incorporated hormonal therapy (tamoxifen), included microinvasive disease, and was a 2 Â2 randomization such that patients following BCS could undergo observation, WBI, tamoxifen, or WBI plus tamoxifen. The results of this trial demonstrated that WBI reduced the rates of IBTR (19.4% vs. 7.1%) at 12 years with similar reductions noted for invasive and noninvasive IBTRs. 19 A recently published meta-analysis of these 4 trials confirmed the findings of these trials; adjuvant WBI was found to reduce the rates of IBTR compared with observation (13% vs. 28%). 31 These findings were confirmed by a second meta-analysis that identified a 50% reduction in local recurrences with similar rates of reduction noted for invasive and noninvasive recurrences. 33 More recently, 2 single-arm studies and 1 randomized trial have been conducted to further evaluate the efficacy of omitting adjuvant RT after BCS in highly selected, "low-risk patients" as defined by pathologic characteristics (ie, tumor size, margin status, nuclear grade). The first trial was performed at the Dana Farber Cancer Institute (DFCI) and enrolled 158 patients with low-grade/intermediate-grade DCIS measuring r2.5 cm with surgical margins >1 cm; of note, no endocrine therapy was allowed on this trial. This study was closed early due to a higher than expected rate of local recurrence (5 y IBTR rate of 12%) with subsequent follow-up demonstrating 8-and 10-year local recurrence rates of 13% and 15.6%, respectively. 34 The Eastern Cooperative Oncology Group (ECOG) E-5194 trial enrolled 670 patients with lowgrade/intermediate-grade DCIS that was 2.5 cm or smaller or high-grade DCIS that was 1 cm or smaller with all cases requiring 3 mm or wider surgical margins. Unlike the DFCI study, tamoxifen use was allowed following a protocol amendment in 2000 (30% of cases). At 5 years, the rates of IBTR were 6.1% and 15.3% and at 10 years 15.4% and 15.1%, respectively, for the low-grade/intermediate-grade and highgrade cohorts. 35 A recent analysis was performed using the ECOG criteria and compared outcomes between those receiving RT (single institution retrospective cohort) and those treated with excision alone (ECOG cohort); in the low-grade/ intermediate-grade (4.4% vs. 10.5%) and high grade (2.0% vs. 18.0%) subsets, RT reduced the rates of IBTR. 36 The RTOG 9804 trial was a phase III study, which utilized eligibility criteria similar to the ECOG study (mammographically detected, low-grade/intermediate-grade DCIS, r2.5 cm, and Z3 mm margins) and randomized patients to observation or adjuvant RT after excision with or without tamoxifen. This trial closed in 2006, secondary to poor accrual enrolling only 35% of its intended goal (636/1790 patients). At 5 years, RT was associated with a significant reduction in the rate of IBTR (0.4% vs. 3.2%). Evaluating patterns of failure in this study found that two thirds of recurrences in the observation-alone arm were true recurrences (in the same quadrant as the initial tumor), whereas none of the recurrences in the RT arm were true recurrences. 20 Multiple retrospective studies have also evaluated outcomes with BCS alone. One of the largest retrospective series comes from a pooled analysis of the French Regional Cancer Centers; 705 patients were treated with excision alone or with RT between 1985 and 1995. With a median follow-up of 7 years, the IBTR rate was 32.4% for excision alone compared with 12.6% with RT. 37 Higher rates of local recurrence were also noted in a review from Ontario, which found a 19% rate of local recurrence with excision alone compared with 13% with adjuvant RT, with over 3500 patients evaluated. 25 One of the most complete long-term studies on excision alone for DCIS comes from the University of Southern California. Findings from these studies resulted in the development of the Van Nuys Prognostic Index (VNPI). In the initial study, 333 patients were treated with BCS with (n = 138) or without the addition of RT (n = 195) and were assigned VNPI scores of 3 to 9 based on tumor size, margin, and histologic classification. The initial analysis found that for patients with VNPI scores of 3 to 4, no benefit to RT following BCS was noted, whereas for patients with VNPI scores of 5 to 7, a 17% benefit in local control was observed with the addition of RT. Patients with VNPI scores of 8 to 9 had large benefits with RT but were recommended to undergo mastectomy due to high rates of IBTR regardless of treatment. 38 Subsequent updates of these results have led to the addition of patient age to the VNPI with comparable findings noted in terms of low-risk (VNPI 4 to 6, excision alone equivalent to BCT), intermediate-risk (VNPI 7 to 9, RT reduces local recurrences) and high-risk patients (VNPI 10 to 12, mastectomy recommended). 39, 40 A recent update from the group evaluated 205 patients, 50 years or older with grade 1 to 2 tumors <2 cm treated with excision alone; the 6-and 12year rates of local recurrence were 6.6% and 7.8%, respectively. 41 A summary of studies evaluating excision alone are presented in Table 2 .
Identifying a "Low-risk" Patient
Multiple attempts have been made to identify a low-risk subset of patients with DCIS that would require excision only.
It should be noted that randomized trials and analyses have failed to identify a low-risk subset that did not benefit from adjuvant RT with respect to local control; analysis of NSABP B-17 did find that comedonecrosis, solid tumor-type DCIS, moderate/marked lymphoid infiltrate, and multifocality were associated with IBTR with a trend for uncertain/involved margins. [16] [17] [18] 30, 31, 42 Further, the recently published RTOG 9804 that enrolled "low-risk" patients still found a significant benefit to the addition of adjuvant RT despite being underpowered and having short follow-up at this time, whereas single-arm prospective trials have demonstrated unacceptably high rates of LR, even with "low-risk" patients. 20, 34, 35 To this end, there exists no standardized or universally accepted pathologic definition of "low risk" as it pertains to the omission of RT for patients with DCIS. Currently, neither the National Comprehensive Cancer Network DCIS guidelines nor the American College of Radiology specify a set of criteria to identify low-risk patients suitable for observation alone following BCS, which has been confirmed by a recently updated German evidence-based guideline. 2, 43, 44 Initial attempts to identify low-risk patients were based on clinical/pathologic characteristics based on data demonstrating associations between such factors (size, margin, grade, and age) and local recurrence. 45, 46 One such attempt discussed above is the use of the VNPI. [38] [39] [40] However, the VNPI has not been successfully validated and its external reproducibility and applicability remain controversial. [47] [48] [49] [50] Another riskstratification model comes from a nomogram developed at Memorial Sloan Kettering Cancer Center, which incorporates age, clinical presentation, tumor grade, necrosis, margin status, receipt of RT, family history, receipt of endocrine therapy, and year of treatment into a composite score between 0 and 500; each factor is weighted based on its impact on rates of IBTR with the key factors being receipt of RT and receipt of endocrine therapy. 51 Unfortunately, no evaluation of outcomes for patients receiving BCS alone compared with adjuvant RT by nomogram score has been performed to date to identify a lowrisk score and the nomogram's ability to accurately predict the rate of recurrence has been switch to questioned. 52 When looking at older patients (above 66 y old) who have traditionally been associated with lower rates of local recurrence, Smith and colleagues still found a benefit to adjuvant RT among low-risk patients with an 8.2% rate of local recurrence without RT compared with 1% with RT. 53 37 1985-1995 705 84 32.4% (7 y) University of Southern California [38] [39] [40] 1996-2003 426 81 24% (10 y) VNPI 4-6: 3% (10 y) VNPI 7-9: 27% (10 y) VNPI 10-12: 66% (10 y) Ontario 25 1994-2003 1,867 120 19.0% (10 y)
A future direction in the identification of a low-risk subset of DCIS patients is to move beyond traditional clinical and pathologic risk factors and utilize tumor genetics to better identify patients at low risk for local recurrence. Previously, multigene assays have been developed for patients with invasive cancers; initially, these assays were not designed to be utilized in patients with DCIS. [54] [55] [56] However, a recent analysis of a new 21-gene assay designed for patients with DCIS has been performed incorporating data from the ECOG E-5194 trial and found the rates of IBTR in the low-risk and intermediate-risk groups to be 4% and 12%, respectively, at 10 years. 35, 57 An alternative methodology is to build upon current prognostic models by incorporating biomarkers; such a technique was performed by Altintas et al 58 by utilizing the VNPI and evaluating the impact of Ki-67 and genomic grade index; the genomic grade index when used in conjunction with the VNPI was found to more accurately identify high-risk cases. However, several series have failed to identify biomarkers that are associated with local recurrence. 46, 59 HER2 is also being evaluated as a biomarker for prognosis and response to adjuvant therapy; currently, the NSABP is enrolling patients with DCIS to undergo centralized HER2 testing and subsequent randomization for those that are HER2 + to RT with or without trastuzumab. 60 Moving forward, more studies are required to confirm the prognostic ability of these assays and biomarkers; should they be confirmed, patients with low-risk molecular/ genetic profiles will have to be prospectively evaluated to determine whether excision alone results in acceptable rates of long-term local control. Table 3 summarizes studies that have attempted to identify a low-risk cohort and the results of such stratifications.
The Role of Mastectomy in DCIS
Mastectomy represents the traditional management technique for DCIS and still remains an appropriate therapeutic option in selected cases. Currently, the utilization of mastectomy in DCIS is often limited to patient preference, cases where the patient is unable to undergo BCS (ie, diffuse microcalcifications, multicentric disease, and/or persistently positive margins, etc.), and, at some institutions, patients who are felt to have "high-risk" DCIS. 2,38 Long-term outcomes following mastectomy have consistently demonstrated local recurrence rates <5% and cause-specific survival rates >95% (Table 4 ). [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] As previously noted, no randomized trials are available directly comparing mastectomy and BCT for DCIS, with limited published data of any type directly comparing the 2 techniques. A meta-analysis from Boyages et al 76 found that the recurrence rates after mastectomy, BCS with RT, and BCS alone were 1.4%, 8.9%, and 22.5%, respectively; however, this included a wide variety studies with no control for clinical or pathologic features by treatment technique. Although local control rates are inconsistent between studies, a second meta-analysis and several analyses have confirmed no difference in survival or cancer mortality between techniques. 61, 65, 67, [72] [73] [74] [75] 77 Taken together, no difference in survival or cancer-specific survival have been noted with BCT compared with mastectomy, and based on the data available BCT remains the standard of care in the management of DCIS. 61, 76, 77 
DISCUSSION/CONCLUSIONS
At this time, BCT, consisting of BCS followed by adjuvant RT, represents the standard of care in the management of patients with DCIS based on the publication of several randomized trials documenting improvement in local control with adjuvant RT. Over the past 2 decades, several trials have attempted to identify a "low-risk" cohort of DCIS patients who may be safely treated with excision alone, but have consistently demonstrated an increase in the rate of local failure with the omission of RT and failed to identify a consistent and reproducible subset of patients that does not benefit from adjuvant radiation. Genetic assays and biomarkers are the prognostic tools of the future but require further study and validation before widespread clinical use. Unfortunately, up to 50% of patients are not receiving adjuvant RT despite clinical guideline recommendation. At this time, adjuvant RT should be advocated for most women who present with DCIS based on the consistent benefit in local control it provides and the inability to accurately identify truly low-risk patients; omitting RT should only be offered on-protocol with an increased focus placed on ensuring RT access for women who desire breast conservation. Future research will need to evaluate not only local control but examine long-term survival and the balance between survival outcomes and quality of life following treatment.
